Brokerages predict that Viking Therapeutics Inc (NASDAQ:VKTX) will announce earnings of ($0.19) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Viking Therapeutics’ earnings. The lowest EPS estimate is ($0.20) and the highest is ($0.19). Viking Therapeutics posted earnings per share of ($0.18) in the same quarter last year, which would indicate a negative year-over-year growth rate of 5.6%. The company is scheduled to report its next quarterly earnings results on Tuesday, March 20th.
On average, analysts expect that Viking Therapeutics will report full-year earnings of ($0.86) per share for the current year, with EPS estimates ranging from ($0.87) to ($0.85). For the next fiscal year, analysts forecast that the business will report earnings of ($0.68) per share, with EPS estimates ranging from ($0.72) to ($0.60). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Viking Therapeutics.
VKTX has been the topic of several research reports. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Viking Therapeutics in a report on Friday, November 10th. Roth Capital initiated coverage on shares of Viking Therapeutics in a report on Tuesday, November 21st. They set a “buy” rating and a $5.00 price objective on the stock. Maxim Group set a $8.00 price objective on shares of Viking Therapeutics and gave the stock a “buy” rating in a report on Tuesday, November 28th. ValuEngine downgraded shares of Viking Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, BidaskClub upgraded shares of Viking Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Viking Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $7.00.
Several institutional investors have recently modified their holdings of the company. Citadel Advisors LLC acquired a new stake in shares of Viking Therapeutics during the 3rd quarter valued at about $108,000. Creative Planning boosted its position in shares of Viking Therapeutics by 600.0% during the 4th quarter. Creative Planning now owns 70,000 shares of the biotechnology company’s stock valued at $284,000 after acquiring an additional 60,000 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Viking Therapeutics by 276.2% during the 4th quarter. Geode Capital Management LLC now owns 117,619 shares of the biotechnology company’s stock valued at $477,000 after acquiring an additional 86,355 shares in the last quarter. Cornerstone Capital Inc. acquired a new stake in shares of Viking Therapeutics during the 4th quarter valued at about $352,000. Finally, Virtu KCG Holdings LLC acquired a new stake in shares of Viking Therapeutics during the 2nd quarter valued at about $124,000. Institutional investors and hedge funds own 11.72% of the company’s stock.
Shares of Viking Therapeutics (NASDAQ VKTX) traded down $0.05 on Thursday, reaching $6.18. 2,325,100 shares of the company traded hands, compared to its average volume of 1,629,513. Viking Therapeutics has a 12-month low of $0.88 and a 12-month high of $7.15. The company has a market cap of $290.76, a P/E ratio of -7.36 and a beta of 2.26.
COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Expect Viking Therapeutics Inc (VKTX) to Post -$0.19 EPS” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/20/zacks-analysts-expect-viking-therapeutics-inc-vktx-to-post-0-19-eps.html.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
Get a free copy of the Zacks research report on Viking Therapeutics (VKTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.